Quan Capital
Quan Capital is a healthcare focused venture capital firm.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Quan Capital Information
Geographic Data
Address: 4560 Jinke Road, Zhangjiang Hi-tech Park
City: Shanghai
State: shanghai municipality
Zip: 201210
Country: CN
Financial Info
Stage:
Raised Last:
$0
Raised Total:$275M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Quan Capital discover, incubate and grow next-generation life sciences companies. Their unique investment philosophy enables us to explore disruptive solutions to critical healthcare problems impacting the lives of millions. Their portfolio companies are pioneers in breakthrough therapies and cutting-edge technologies that will generate significant value to patients. In addition, they are investing in leading players that fulfill the rapid growing needs in a nascent innovation driven eco-system in China.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2022 | Yuanyin Bio | Series A | 0 |
| 11/2020 | Kira Pharmaceuticals | Venture Round | - |
| 3/2021 | Zenas BioPharma | Series A | - |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 9/2021 | Walking Fish Therapeutics | Series A | 50M |
| 8/2017 | ARMO BioSciences | Series C | 0 |
| 3/2021 | Innoforce Pharmaceuticals | Series A | 96M |
| 12/2021 | Innoforce Pharmaceuticals | Series A | 0 |
| 7/2017 | Qiagen Suzhou Translational Medicine | Series A | 0 |
| 3/2020 | Design Therapeutics | Series A | 45.5M |
| 1/2018 | Centrexion | Series D | 67M |
| 10/2019 | Arcellx | Series B | 0 |
| 5/2021 | Alebund Pharmaceuticals | Series B | 0 |
| 11/2017 | resTORbio | Series A | 40M |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 11/2020 | Eluminex Biosciences | Series A | 50M |
| 8/2022 | OriginCell | Series B | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 11/2018 | NextCure | Series B | 93M |
| 3/2018 | Tempest Therapeutics | Series B | 70M |
| 7/2020 | Citrine Medicine | Series A | 0 |
| 4/2023 | Alebund Pharmaceuticals | Series C | 0 |
| 9/2021 | Alebund Pharmaceuticals | Series B | 0 |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 11/2021 | Yuanyin Bio | Seed Round | 0 |
| 8/2022 | Oricell Therapeutics | Series B | 120M |
| 1/2018 | Gonbike | Angel Round | 15M |
| 1/2021 | Kira Pharmaceuticals | Series B | 53.5M |
| 8/2022 | OriginCell | Series B | 0 |
| 8/2022 | Oricell Therapeutics | Series B | 0 |
| 6/2022 | Yuanyin Bio | Series A | 0 |
| 12/2021 | Innoforce Pharmaceuticals | Series A | 0 |
| 11/2021 | Yuanyin Bio | Seed Round | 0 |
| 9/2021 | Alebund Pharmaceuticals | Series B | 0 |
| 9/2021 | Walking Fish Therapeutics | Series A | 0 |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 5/2021 | Alebund Pharmaceuticals | Series B | 0 |
| 3/2021 | Innoforce Pharmaceuticals | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
